Pfizer plans to invest $5bn across the US, begins with $465m facility

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/EasternLightcraft)
(Image: Getty/EasternLightcraft)

Related tags: Pfizer, Sterile Injectables, President Trump

Pfizer has revealed it will invest $5bn to support operations in the US, with the first step being the construction of a 400,000-square-foot production facility, costing $465m.

The new sterile injectable facility will create more than 450 jobs in Portage, Kalamazoo County – joining the 2,200 Pfizer employees currently working in the city.

According to the press release​, the $465m (€397m) facility will “be one of the most technically advanced sterile injectable pharmaceutical production facilities in the world”.

The facility will include multiple, self-contained modular manufacturing lines, which will allow each line, in each module, to work in isolation from other manufacturing lines.

Ground-breaking on the project is expected to take place in spring 2019 and construction is planned to be completed in 2021. Production at the facility was noted to begin in 2024, contingent on regulatory approval.

Pfizer's plant in Portage currently produces sterile injectable, liquids and semi-solid medicines, and active pharmaceutical ingredients (APIs).

The new development in Portage has been supported at the state level by tax breaks worth $10.5m​ and an additional $1m ‘performance-based grant’ agreed by the Michigan Strategic Fund Board.

More to come

A spokesperson for Pfizer outlined to us that this is the first of more such projects, “Following passage of the US tax reform, we announced that over the next five years, we plan to invest approximately $5bn in capital projects in the US, including the strengthening of our manufacturing presence in the US.”

The spokesperson continued, “We expect to invest approximately $1.1bn in Kalamazoo County – which is in addition to the $1 billion we have invested in the site over the past decade with tax reform having a favourable influence on our investments in Kalamazoo.”

The spokesperson did not reveal in what particular projects the total $5bn will be invested.

One of President Trump’s main calling cards for the pharmaceutical industry has been to return manufacturing to the US​ and Pfizer’s actions, spurred by the tax reform, corroborate statements made by other companies​ that this will happen.

Related topics: Delivery formulations, Ingredients

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us

Products

View more